Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 04 05 2022
accepted: 10 06 2022
entrez: 28 7 2022
pubmed: 29 7 2022
medline: 30 7 2022
Statut: epublish

Résumé

Deficiency of Adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disorder presenting with a broad spectrum of clinical manifestations, including immunodeficiency, vasculopathy and hematologic disease. Biallelic mutations in ADA2 gene have been associated with a decreased ADA2 activity, leading to reduction in deamination of adenosine and deoxyadenosine into inosine and deoxyinosine and subsequent accumulation of extracellular adenosine. In the early reports, the pivotal role of innate immunity in DADA2 pathogenic mechanism has been underlined, showing a skewed polarization from the M2 macrophage subtype to the proinflammatory M1 subtype, with an increased production of inflammatory cytokines such as TNF-α. Subsequently, a dysregulation of NETosis, triggered by the excess of extracellular Adenosine, has been implicated in the pathogenesis of DADA2. In the last few years, evidence is piling up that adaptive immunity is profoundly altered in DADA2 patients, encompassing both T and B branches, with a disrupted homeostasis in T-cell subsets and a B-cell skewing defect. Type I/type II IFN pathway upregulation has been proposed as a possible core signature in DADA2 T cells and monocytes but also an increased IFN-β secretion directly from endothelial cells has been described. So far, a unifying clear pathophysiological explanation for the coexistence of systemic inflammation, immunedysregulation and hematological defects is lacking. In this review, we will explore thoroughly the latest understanding regarding DADA2 pathophysiological process, with a particular focus on dysregulation of both innate and adaptive immunity and their interacting role in the development of the disease.

Identifiants

pubmed: 35898506
doi: 10.3389/fimmu.2022.935957
pmc: PMC9309328
doi:

Substances chimiques

Intercellular Signaling Peptides and Proteins 0
Adenosine Deaminase EC 3.5.4.4
Adenosine K72T3FS567

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

935957

Informations de copyright

Copyright © 2022 Signa, Bertoni, Penco, Caorsi, Cafaro, Cangemi, Volpi, Gattorno and Schena.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

RMD Open. 2016 May 16;2(1):e000236
pubmed: 27252897
J Autoimmun. 2016 Aug;72:8-18
pubmed: 27157273
J Allergy Clin Immunol. 2018 Apr;141(4):1534-1537.e8
pubmed: 29391253
Semin Hematol. 2022 Jan;59(1):13-20
pubmed: 35491054
Molecules. 2021 Sep 21;26(18):
pubmed: 34577178
Cells. 2022 Mar 17;11(6):
pubmed: 35326467
J Rheumatol. 2015 Aug;42(8):1532-4
pubmed: 26233953
Rheumatology (Oxford). 2016 May;55(5):902-10
pubmed: 26867732
Rheumatology (Oxford). 2021 Sep 1;60(9):4373-4378
pubmed: 33420503
J Clin Immunol. 2018 Jul;38(5):569-578
pubmed: 29951947
Clin Immunol. 2020 Sep;218:108525
pubmed: 32659374
J Leukoc Biol. 2022 Feb;111(2):301-312
pubmed: 34730257
Adv Protein Chem Struct Biol. 2022;129:91-133
pubmed: 35305726
Pediatr Rheumatol Online J. 2017 Aug 22;15(1):67
pubmed: 28830446
J Pediatr Hematol Oncol. 2017 Jul;39(5):e293-e296
pubmed: 28230570
J Allergy Clin Immunol. 2021 Aug;148(2):550-562
pubmed: 33529688
J Lab Clin Med. 1977 Nov;90(5):844-8
pubmed: 409794
Front Immunol. 2022 May 03;13:869570
pubmed: 35592317
Blood Adv. 2021 Aug 24;5(16):3174-3187
pubmed: 34424322
Clin Chem. 2020 Apr 1;66(4):525-536
pubmed: 32176780
Arthritis Rheumatol. 2019 Oct;71(10):1747-1755
pubmed: 31008556
J Clin Immunol. 2021 Apr;41(3):680-683
pubmed: 33394316
Front Immunol. 2022 Jan 10;12:811473
pubmed: 35095905
Nat Rev Immunol. 2011 Mar;11(3):201-12
pubmed: 21331080
Front Immunol. 2022 Apr 22;13:852830
pubmed: 35529868
J Clin Invest. 1990 Apr;85(4):1150-7
pubmed: 2156895
Pediatr Rheumatol Online J. 2014 Sep 24;12:44
pubmed: 25278816
Clin Chim Acta. 1978 Jan 2;82(1-2):179-84
pubmed: 412622
Clin Immunol. 2020 Jun;215:108443
pubmed: 32353633
Arthritis Rheumatol. 2019 Dec;71(12):2047-2058
pubmed: 31313503
J Immunol. 2002 Apr 1;168(7):3536-42
pubmed: 11907116
Anal Biochem. 1990 Jun;187(2):268-72
pubmed: 2382828
N Engl J Med. 2014 Mar 6;370(10):921-31
pubmed: 24552285
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29271561
J Biol Chem. 2010 Apr 16;285(16):12367-77
pubmed: 20147294
J Clin Immunol. 2018 Apr;38(3):273-277
pubmed: 29564582
Blood. 2017 Dec 14;130(24):2682-2688
pubmed: 28974505
Sci Adv. 2020 Jul 22;6(30):eaba3688
pubmed: 32743071
J Leukoc Biol. 2010 Aug;88(2):279-90
pubmed: 20453107
J Clin Immunol. 2020 Aug;40(6):948-953
pubmed: 32643137
J Rheumatol. 2001 Mar;28(3):485-9
pubmed: 11296946
Immunol Invest. 2022 Apr;51(3):558-566
pubmed: 33705245
J Allergy Clin Immunol. 2015 Jan;135(1):283-7.e5
pubmed: 25457153
Arthritis Rheumatol. 2017 Aug;69(8):1689-1700
pubmed: 28493328
J Clin Immunol. 2018 Nov;38(8):836-843
pubmed: 30386947
Arthritis Rheumatol. 2021 Feb;73(2):276-285
pubmed: 32892503
Blood. 2019 Jul 25;134(4):338-339
pubmed: 31345927
Eur J Rheumatol. 2019 Dec 03;:1-8
pubmed: 31804174
J Clin Immunol. 2021 Nov;41(8):1915-1935
pubmed: 34657246
J Clin Immunol. 2018 Feb;38(2):166-173
pubmed: 29411230
Arthritis Rheumatol. 2016 Sep;68(9):2314-22
pubmed: 27059682
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Eur J Immunol. 2021 Jan;51(1):206-219
pubmed: 32707604
Pediatr Blood Cancer. 2022 Jun;69(6):e29461
pubmed: 34811889
N Engl J Med. 2019 Apr 18;380(16):1582-1584
pubmed: 30995379
Arthritis Rheumatol. 2021 Mar;73(3):512-519
pubmed: 33021335
Eur J Hum Genet. 2018 Jul;26(7):960-971
pubmed: 29681619
J Pediatr. 2016 Oct;177:316-320
pubmed: 27514238
Int J Mol Sci. 2021 Mar 08;22(5):
pubmed: 33800290
Ann Rheum Dis. 2015 Jul;74(7):1417-24
pubmed: 24570026
Immunity. 2009 Oct 16;31(4):539-50
pubmed: 19833085
Front Immunol. 2019 Jan 14;9:2767
pubmed: 30692987
Cell Mol Life Sci. 2017 Feb;74(3):555-570
pubmed: 27663683
Med (N Y). 2022 Jan 14;3(1):42-57.e5
pubmed: 35590143
J Rheumatol. 2020 Jan;47(1):117-125
pubmed: 31043544
Biochem J. 2005 Oct 1;391(Pt 1):51-7
pubmed: 15926889
Ann Rheum Dis. 2017 Oct;76(10):1648-1656
pubmed: 28522451
Clin Rheumatol. 2021 Oct;40(10):3883-3896
pubmed: 33791889
J Leukoc Biol. 2021 Sep;110(3):405-407
pubmed: 34137068
J Clin Med. 2019 Aug 28;8(9):
pubmed: 31466329
Adv Protein Chem Struct Biol. 2020;120:1-44
pubmed: 32085880
Annu Rev Pathol. 2019 Jan 24;14:369-393
pubmed: 30332560
Anal Biochem. 2021 Sep 1;628:114292
pubmed: 34171384
J Clin Immunol. 2020 Jan;40(1):223-226
pubmed: 31686313
Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):856-64
pubmed: 22423037
Pediatr Rheumatol Online J. 2020 Jul 10;18(1):54
pubmed: 32650798
J Clin Immunol. 2017 Feb;37(2):123-132
pubmed: 27943079
J Rheumatol. 2019 May;46(5):523-526
pubmed: 30647181
Pathogens. 2021 Jul 19;10(7):
pubmed: 34358058
N Engl J Med. 2014 Mar 6;370(10):911-20
pubmed: 24552284
Blood. 2019 Jul 25;134(4):395-406
pubmed: 31015188
Front Immunol. 2021 Oct 14;12:754029
pubmed: 34721429
J Clin Immunol. 2021 Oct;41(7):1633-1647
pubmed: 34324127
J Leukoc Biol. 2022 Feb;111(2):297-299
pubmed: 35090065
Nature. 1997 Aug 21;388(6644):782-7
pubmed: 9285591
J Allergy Clin Immunol. 2020 Jun;145(6):1664-1672.e10
pubmed: 31945408
J Leukoc Biol. 2021 Sep;110(3):409-424
pubmed: 33988272
J Allergy Clin Immunol. 2022 May;149(5):1812-1816.e6
pubmed: 34780847
Semin Immunopathol. 2022 May;44(3):269-280
pubmed: 35178658
Am J Hum Genet. 2018 Dec 6;103(6):930-947
pubmed: 30503522

Auteurs

Sara Signa (S)

Center for Autoinflammatory Diseases and Immunodeficiencies, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.

Arinna Bertoni (A)

Center for Autoinflammatory Diseases and Immunodeficiencies, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Sciences (DINOGMI), University of Genoa, Genoa, Italy.

Federica Penco (F)

Center for Autoinflammatory Diseases and Immunodeficiencies, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.

Roberta Caorsi (R)

Center for Autoinflammatory Diseases and Immunodeficiencies, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.

Alessia Cafaro (A)

Chromatography and Mass Spectrometry Section, Central Laboratory of Analysis, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.

Giuliana Cangemi (G)

Chromatography and Mass Spectrometry Section, Central Laboratory of Analysis, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.

Stefano Volpi (S)

Center for Autoinflammatory Diseases and Immunodeficiencies, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Sciences (DINOGMI), University of Genoa, Genoa, Italy.

Marco Gattorno (M)

Center for Autoinflammatory Diseases and Immunodeficiencies, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.

Francesca Schena (F)

Center for Autoinflammatory Diseases and Immunodeficiencies, Istituto di Ricovero e cura a carattere scientifico (IRCCS) Istituto Giannina Gaslini, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH